These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21842452

  • 21. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.
    Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, Skidmore B, Moher D, Alvarez GG.
    BMC Infect Dis; 2017 Apr 11; 17(1):265. PubMed ID: 28399802
    [Abstract] [Full Text] [Related]

  • 22. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial.
    Chan PC, Yang CH, Chang LY, Wang KF, Lu BY, Lu CY, Shao PL, Hsueh PR, Fang CT, Huang LM.
    Int J Tuberc Lung Dis; 2012 May 11; 16(5):633-8. PubMed ID: 22410137
    [Abstract] [Full Text] [Related]

  • 23. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic.
    Jinbo J, Lustik M, West GF, Kloetzel M.
    Mil Med; 2017 Sep 11; 182(9):e2024-e2029. PubMed ID: 28885972
    [Abstract] [Full Text] [Related]

  • 24. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.
    Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB.
    Chest; 2006 Dec 11; 130(6):1712-7. PubMed ID: 17166986
    [Abstract] [Full Text] [Related]

  • 25. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
    Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ.
    Ann Intern Med; 2017 Aug 15; 167(4):248-255. PubMed ID: 28761946
    [Abstract] [Full Text] [Related]

  • 26. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2001 Aug 31; 50(34):733-5. PubMed ID: 11787580
    [Abstract] [Full Text] [Related]

  • 27. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D.
    Lancet Infect Dis; 2020 Mar 31; 20(3):318-329. PubMed ID: 31866327
    [Abstract] [Full Text] [Related]

  • 28. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA, de Souza-Galvao ML, Mila Augé C, Solsona Peiró J, Altet-Gómez MN.
    Int J Tuberc Lung Dis; 2013 Mar 31; 17(3):326-32. PubMed ID: 23407221
    [Abstract] [Full Text] [Related]

  • 29. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H, Mohri M.
    Kekkaku; 2003 Apr 31; 78(4):339-46. PubMed ID: 12739393
    [Abstract] [Full Text] [Related]

  • 30. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection.
    Miyazawa S, Matsuoka S, Hamana S, Nagai S, Nakamura H, Nirei K, Moriyama M.
    Intern Med; 2015 Apr 31; 54(6):591-5. PubMed ID: 25786447
    [Abstract] [Full Text] [Related]

  • 31. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
    Schein YL, Madebo T, Andersen HE, Arnesen TM, Dyrhol-Riise AM, Tveiten H, White RA, Winje BA.
    BMC Infect Dis; 2018 Nov 19; 18(1):587. PubMed ID: 30453946
    [Abstract] [Full Text] [Related]

  • 32. Latent tuberculosis treatment completion rates from prescription drug administrative data.
    Plourde PJ, Basham CA, Derksen S, Schultz J, McCulloch S, Larcombe L, Kinew KA, Lix LM.
    Can J Public Health; 2019 Dec 19; 110(6):705-713. PubMed ID: 31297736
    [Abstract] [Full Text] [Related]

  • 33. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons.
    Schmit KM, Lobato MN, Lang SG, Wheeler S, Kendig NE, Bur S.
    J Public Health Manag Pract; 2019 Dec 19; 25(2):E1-E6. PubMed ID: 30024493
    [Abstract] [Full Text] [Related]

  • 34. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates.
    de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP.
    Transplantation; 2014 Jan 27; 97(2):206-11. PubMed ID: 24142036
    [Abstract] [Full Text] [Related]

  • 35. Latent tuberculosis in childhood: tolerability of two different therapeutic approaches.
    Tersigni C, Venturini E, Cordola C, Piccini P, Bianchi L, Montagnani C, Sollai S, Chiappini E, de Martino M, Galli L.
    Expert Rev Anti Infect Ther; 2018 Apr 27; 16(4):359-365. PubMed ID: 29465259
    [Abstract] [Full Text] [Related]

  • 36. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK, Sharma A, Kadhiravan T, Tharyan P.
    Evid Based Child Health; 2014 Mar 27; 9(1):169-294. PubMed ID: 25404581
    [Abstract] [Full Text] [Related]

  • 37. Hepatoprotective effect of Anacyclus pyrethrum Linn. against antitubercular drug-induced hepatotoxicity in SD rats.
    Usmani A, Mujahid M, Khushtar M, Siddiqui HH, Rahman MA.
    J Complement Integr Med; 2016 Sep 01; 13(3):295-300. PubMed ID: 27101559
    [Abstract] [Full Text] [Related]

  • 38. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A, Long R, Zylberberg D, Dion MJ, Al-Otaibi B, Menzies D.
    Int J Tuberc Lung Dis; 2010 May 01; 14(5):551-9. PubMed ID: 20392347
    [Abstract] [Full Text] [Related]

  • 39. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.
    Ronald LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, Benedetti A, Boivin JF, Menzies D.
    Eur Respir J; 2020 Mar 01; 55(3):. PubMed ID: 31980498
    [Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A.
    Respir Med; 2013 May 01; 107(5):768-77. PubMed ID: 23490222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.